Deutsche Bank cut its price target for ACADIA Pharmaceuticals to $27 but still rates it as a Buy.

Nov 11, 2026, 9:46 AM ETOpinionRead the original at marketscreener.com

Neutral

Deutsche Bank lowered its target from $30 to $27 but kept its Buy rating. Those mixed analyst signals do not change ACAD's business outlook on their own.

ACAD · ACADIA Pharmaceuticals Inc.

AI read · Neutral

The AI's read

This is one firm's estimate, not a change to ACAD's sales, profits, or drug programs. Keeping the Buy rating tempers the lower target, so the report alone does not clearly shift the company's outlook.

Get alerts for ACAD

Follow ACADIA Pharmaceuticals Inc. (ACAD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ACAD

Free on the App Store and Google Play, or on the web.